Skip to main content
Equibles

UBS Group AG

Position in SYRE — Spyre Therapeutics, Inc.

CIK 1610520 ZURICH, V8
Back to SYRE Full portfolio

Position in SYRE

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$74,847,841
+$40,990,749 QoQ
Shares Held
843,071
+25.6% QoQ
Ownership
0.956%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#32
of 266 holders
Holding Since
Dec 2023
11 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in SYRE Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

UBS Group AG holds $8,789,675,801 across 560 Biotechnology names. SYRE ranks #27 (0.9% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 RVMD
Revolution Medicines, Inc.
 5,450,825 $1,020,369,609
2 ROIV
Roivant Sciences Ltd.
 17,466,641 $618,144,423
3 PTGX
Protagonist Therapeutics, Inc
 3,399,221 $416,676,508
4 VRTX
Vertex Pharmaceuticals Inc / Ma
 712,259 $353,800,411
5 MRNA
Moderna, Inc.
 4,463,211 $312,558,664
6 INSM
INSMED Inc
 2,584,446 $275,553,630
7 ABVX
Abivax S.A.
 1,844,918 $245,853,771
8 MDGL
Madrigal Pharmaceuticals, Inc.
 401,708 $215,697,109

All Filings in SYRE

Export CSV
11 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $74,847,841 843,071
2026-03-31 $33,857,092 671,235
2025-12-31 $22,295,341 680,566
2025-09-30 $6,462,470 385,589
2025-06-30 $6,929,059 462,863
2025-03-31 $8,910,440 552,243
2024-12-31 $9,130,345 392,197
2024-09-30 $1,701,014 57,838
2024-06-30 $1,046,289 44,504
2024-03-31 $98,655 2,601
2023-12-31 $80,183 3,726